2025-05-15-Jefferies-Celcuity（CELC）_第一季度2L_mBC三期数据截止于6月_预计2025年第三季度公布关键数据_11页_563kb

Summary of Celcuity (CELC) Document

Core Content

Celcuity (CELC) is a clinical-stage biotechnology company focused on developing targeted cancer therapies using its proprietary CELsignia CDx platform. The company is currently advancing its drug gedatolisib through multiple clinical trials, with key outcomes expected in 2025.

The VIKTORIA-1 phase III trial for gedatolisib in 2L (second-line) PIK3CAwt (wild-type) metastatic breast cancer (mBC) is a major catalyst for the company. The top-line results are expected in 3Q25, with data cutoff in June 2025. The company remains optimistic, as updated simulations suggest the trial could show >10 months PFS and <0.55 HR, which are highly competitive in the 2L CDK4/6-exp WT space.

Main Points

• VIKTORIA-1 Trial:
  • Expected top-line results in 3Q25.
  • PFS data and HR will be presented at a major medical conference (likely ESMO or SABCS).
  • Safety data may also be included in the top-line update, if it can be accurately reflected without affecting future publications.
• Simulation Scenarios:
  • Scenario 1 (Base Case): ~12 months mPFS and ~0.3 HR.
  • Other scenarios show competitive HR potential across different variables.
• Market Impact:
  • The trial outcome is expected to significantly influence the stock price.
  • The estimated price target is $33.00, representing a +204% move from the current price of $10.86.
• Other Trials:
  • VIKTORIA-2 (1L mBC): Expected to open a significant market opportunity for gedatolisib.
  • mCRPC (metastatic castration-resistant prostate cancer): Data from a Phase Ib/II trial is expected in late 2Q25.
  • PIK3CAmut portion of the Phase III trial is expected to report in 4Q25.

Key Financials

• Current Price: $10.86
• Price Target: $33.00 (+204%)
• Market Cap: $467.6M
• Float: 70.3%
• EPS Forecast (2025E): $3.44
• EPS Forecast (2026E): $3.42
• EPS Forecast (2027E): $1.03
• Net Income (2025E): $80,360K
• Net Income (2026E): $240,993K
• Net Income (2027E): $433,250K

Investment Thesis

• Differentiated Approach: Gedatolisib's pan-PI3K/mTOR inhibition approach is seen as unique and potentially more effective than other therapies.
• Market Potential: Success in 2L mBC could expand the addressable market for gedatolisib to include both PIK3CAwt and PIK3CAmut populations.
• Pipeline Outlook: The company is working on multiple indications, including mCRPC and other hormone-driven cancers.

Key Risks

• Competition: While current SERDs are not a major threat, future competition in the PIK3CAwt space may affect market share.
• Efficacy and Safety: The trial outcome is critical; failure could lead to a significant drop in stock price.
• Regulatory and Financial Risks: The company's financial performance and ability to meet milestones may affect investor confidence.

Analysts and Ratings

• Analysts: Maury Raycroft, Amin Makarem, Farzin Haque, James Stamos, Amy Qian.
• Rating: Buy
• Price Target: $33.00
• Risk/Reward: High potential upside if trials succeed, but significant downside if results are negative.

ESG and Sustainability

• The company has implemented a Code of Business Ethics and follows GCP guidelines.
• It is working on improving energy, water, and materials use and reducing greenhouse gas emissions and hazardous waste for ESG initiatives.

Pipeline and Milestones

Product	Event	Timeline
Gedatolisib	Primary completion	June 2025
Gedatolisib	2L Ph.III PIK3CAwt mBC readout	3Q25
Gedatolisib	2L Ph.III PIK3CAmut mBC readout	4Q25
Gedatolisib	Commence enrollment in 1L Ph.III VICTORIA-2	2Q25
Gedatolisib	Ph.Ib/II mCRPC trial initial data	2Q25

Company Description

Celcuity is a clinical-stage biotech company that uses its CELSignia CDx platform to support targeted therapies and discover new indications. The company is focused on pan-PI3K/mTOR inhibition as a strategy to address multiple cancer types.

Valuation Methodology

• Price Target: Based on DCF + probability-adjusted EPS.
• Ratings: Includes Buy, Hold, and Underperform based on expected total return.

Investment Recommendation

• Buy Rating: Indicates the stock is expected to provide 15% or more total return within 12 months.
• Price Target: $33.00.

Risk/Reward Scenarios

• Base Case: $33.00 (+204%)
• Upside Scenario: $89.00 (+720%)
• Downside Scenario: $7.00 (-36%)

Other Disclosures

• Jefferies may have conflicts of interest due to its engagement with the company.
• The report is not intended as a recommended portfolio and is subject to regulatory constraints.
• Ratings History shows a high frequency of Buy ratings, with some Hold and Underperform ratings in the past.

Summary of Key Financial Projections

Year	EPS (2025E)	EPS (2026E)	EPS (2027E)
2025	$3.44	$3.42	$1.03
2026	$3.42	$1.03	-

Year	Net Income (2025E)	Net Income (2026E)	Net Income (2027E)
2025	$80,360K	$240,993K	$433,250K
2026	$240,993K	$433,250K	-
2027	$433,250K	-	-

Key Metrics

• Cash: $205.7M
• Runway: Through 2026
• Operating Expenses: ~$36M
• Expected Approval Timeline: If VIKTORIA-1 is successful, approval could occur by mid-2026.

Conclusion

Celcuity is positioned to benefit significantly from the success of its VIKTORIA-1 trial, which could redefine its market position and lead to substantial growth. The company's strategy, combined with its ESG initiatives and financial projections, supports a Buy rating with a $33.00 price target. However, the outcome of the trial remains the most critical factor in determining the company's future.